Cronos Group Inc (CVE:MJN) Director Michael Ryan Gorenstein acquired 5,000 shares of the stock in a transaction dated Thursday, September 7th. The shares were bought at an average cost of C$2.24 per share, with a total value of C$11,200.00.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at

Separately, Canaccord Genuity set a C$3.00 price objective on Cronos Group and gave the stock a “speculative buy” rating in a research report on Wednesday, July 5th.

About Cronos Group

Cronos Group Inc, formerly PharmaCan Capital Corp, is a Canada-based cannabis company. The Company operates two Licensed Producers (LPs) regulated within Health Canada’s Access to Cannabis for Medical Purposes Regulations (the ACMPR) and holds a portfolio of investments in other Licensed Producers and ACMPR applicants.

Receive News & Ratings for Cronos Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group Inc and related companies with's FREE daily email newsletter.